Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 8/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750094 | 1.00 | PPARA (0.47) | PPARAPPARGPPARDSMN1; SMN2MEN1 | |
| SCHEMBL6746594 | 1.00 | PPARA (0.47) | PPARAPPARGPPARDSMN1; SMN2MEN1 | |
| SCHEMBL6746903 | 0.87 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL6747533 | 0.85 | PPARG (0.66) | PPARAPPARGPPARD | |
| SCHEMBL6747805 | 0.84 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL6746410 | 0.84 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL6746407 | 0.84 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL9784540 | 0.84 | LMNA (0.53) | PPARAPPARGPPARDSMN1; SMN2MEN1 | |
| SCHEMBL10889567 | 0.84 | LMNA (0.53) | PPARAPPARGPPARDSMN1; SMN2MEN1 | |
| SCHEMBL6743512 | 0.83 | PPARA (0.51) | PPARAPPARGPPARDMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699904-B2 | PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID | PFIZER INC. | 2004-03-02 | — | — | US | claimed |
| EP-1360172-A1 | PPAR AGONISTS | Pfizer Products Inc. (US) | 2003-11-12 | — | — | EP | claimed |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | HAYWARD CHERYL M (US) | 2002-11-07 | — | — | US | claimed |
| WO-2002064549-A1 | PPAR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | claimed |
| US-6699904-B2 | PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1360172-A1 | PPAR AGONISTS | Pfizer Products Inc. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | HAYWARD CHERYL M (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002064549-A1 | PPAR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.